Core Viewpoint - Alpha Enterprises (00948) has successfully completed a placement of 28 million shares at a price of HKD 0.24 per share, with the proceeds intended to support the expansion of its dairy product business [1] Group 1: Share Placement Details - The share placement was completed on November 14, 2025, with the placement agent successfully distributing shares to no fewer than six subscribers [1] - The total net proceeds from the placement, after deducting expenses, amounted to HKD 6.29 million [1] - The subscription price for the shares was set at HKD 0.24 per share [1] Group 2: Use of Proceeds - The net proceeds from the placement are planned to be used to support the expansion of the company's dairy product business [1]

Core Viewpoint - Alpha Enterprises (00948) has successfully completed a placement of 28 million shares at a price of HKD 0.24 per share, with the proceeds intended to support the expansion of its dairy product business [1] Group 1: Share Placement Details - The share placement was completed on November 14, 2025, with the placement agent successfully distributing the shares to no fewer than six subscribers [1] - The subscription agreement conditions have been fully met, and the completion was finalized on November 25, 2025 [1] - The seller, a wholly-owned subsidiary of Miracle Planet Developments Limited, subscribed for and received 28 million shares at the same price of HKD 0.24 per share [1] Group 2: Financial Implications - The net proceeds from the subscription, after deducting expenses, totaled HKD 6.29 million [1] - The company plans to utilize the net proceeds to support the expansion of its dairy product business [1]

Core Viewpoint - China Hongqiao (01378.HK) has announced a placement and subscription agreement with its controlling shareholder, Hongqiao Holdings, and placement agents, including UBS Group, CMB International, and CITIC Securities International, to issue up to 400 million shares at a price of HKD 29.20 per share, representing approximately 4.20% of the existing issued share capital as of the announcement date [1][2] Group 1 - The placement agents have conditionally agreed to place the shares to independent subscribers based on a best-efforts basis [1] - Hongqiao Holdings has conditionally agreed to subscribe for the same number of shares as those placed under the agreement [1] - The completion of the subscription is subject to conditions, including the approval of the Hong Kong Stock Exchange for the listing and trading of the subscription shares [2] Group 2 - The estimated net proceeds from the subscription, assuming the full placement of 400 million shares, will be approximately HKD 11.49 billion [2] - The company intends to use the net proceeds for the development and enhancement of domestic and overseas projects, repayment of existing debts to optimize its capital structure, and for general corporate purposes [2]

Core Viewpoint - China Hongqiao (01378) announced a placement and subscription agreement with its controlling shareholder, Hongqiao Holdings, on November 17, 2025, to issue shares at a discount to the market price [1] Group 1: Placement and Subscription Agreement - The placement agent conditionally agreed to place shares held by Hongqiao Holdings to independent subscribers at a price of HKD 29.20 per share, which represents a discount of approximately 9.60% compared to the closing price of HKD 32.30 on the same date [1] - Hongqiao Holdings conditionally agreed to subscribe for shares at the same price, and the company will issue these subscription shares under the terms of the agreement [1] Group 2: Financial Implications - Assuming the subscription involves the issuance of 400 million shares, the net proceeds from the subscription are expected to be approximately HKD 11.49 billion [1] - The company plans to use the net proceeds for the development and enhancement of domestic and overseas projects, repayment of existing debts to optimize its capital structure, and for general corporate purposes [1]

Core Viewpoint - The company, Giant Star Legend (06683.HK), has announced a placement and subscription agreement involving the sale of shares at a price of HKD 7.20 per share, potentially raising significant funds for various initiatives [1][2] Group 1: Placement and Subscription Agreement - The seller, including the company's executive director and major shareholder, has appointed the placement agents to facilitate the sale of up to 75 million shares, which represents approximately 8.36% of the total issued shares as of the announcement date [1] - The seller holds 99.65 million shares and 20.52 million shares, accounting for approximately 11.11% and 2.29% of the company's issued share capital, respectively [1] Group 2: Use of Proceeds - The total expected gross proceeds from the subscription are HKD 392.4 million, with a net amount of HKD 369.3 million anticipated [2] - The allocation of the net proceeds includes 67.70% for hosting international concerts and exhibitions, 16.25% for creating unique star IP and related content, 6.06% for research and procurement of food and beverage products, and 9.99% for general working capital and corporate purposes [2]

Core Viewpoint - The company, Hengtai (00197), has successfully completed its placement and subscription matters, raising approximately HKD 14.6 million in total funds through the issuance of shares at a price of HKD 0.476 per share [1] Group 1: Placement and Subscription Details - The placement involved the successful sale of a total of 30.605 million shares to no fewer than six subscribers, representing approximately 14.63% of the company's enlarged issued share capital after the completion of the subscription [1] - The total amount raised from the subscription was approximately HKD 14.6 million, with a net amount of about HKD 14.2 million [1] Group 2: Use of Proceeds - The company plans to utilize the net proceeds from the subscription as follows: approximately HKD 7.5 million for renovations of its logistics center in Shanghai, China, and for upgrading furniture and logistics equipment by October 31, 2026 [1] - Approximately HKD 2.7 million will be allocated for the procurement of new equipment and expanding the workforce at the Dongguan processing center by October 31, 2026 [1] - About HKD 4 million is designated for general working capital, including employee salaries, office rent, and other administrative expenses, to be utilized by June 30, 2026 [1]

Group 1 - The company plans to sell a total of 22.5 million shares, representing approximately 2.03% of the company's issued share capital after subscription [2] - The purchase price of HKD 32.55 per share reflects a discount of about 7.00% compared to the closing price of HKD 35.00 on August 20, 2025 [2] - The estimated net proceeds from the subscription are approximately HKD 722 million, which will be used for exploration and development projects related to the Jinling Mine and general working capital [2][3] Group 2 - The company has entered into an agreement with Victor Soar Investments Limited and Prominence Investment Holding Company Limited for the sale of shares [3] - The agreement includes provisions for the sale of 7.5 million shares at the same price of HKD 32.55 per share, which represents about 0.69% of the company's issued share capital as of the announcement date [3] - The placement agent will facilitate the purchase of shares by at least six subscribers on a best-efforts basis [3]

Core Points - The company completed the placement and subscription matters on July 30, 2025, and August 5, 2025, respectively [1] - A total of 37.5245 million shares were placed, representing approximately 4.18% of the enlarged issued share capital after the subscription [1] - The placement was successfully executed at a price of HKD 9.13 per share to no fewer than six subscribers [1] - The subscription also involved 37.5245 million shares, which were issued to the seller, with net proceeds from the subscription amounting to approximately HKD 324 million [1]

Core Viewpoint - The company, Akeso Inc. (09939), announced a share placement agreement involving the sale of 20.673 million shares at a price of HKD 2.08 per share, representing approximately 4.62% of the company's issued share capital as of the announcement date [1] Group 1 - The seller, KT International Investment Limited, agrees to sell 20.673 million shares, and the placement agent will use its best efforts to facilitate the purchase by buyers at the specified price [1] - The placement price of HKD 2.08 represents a discount of approximately 18.75% compared to the closing price of HKD 2.56 on July 31, 2025 [1] - The estimated net proceeds from the placement are approximately HKD 40.34 million, which will be used for general working capital and business purposes [1] Group 2 - The placement agent has conditionally agreed to act on behalf of the seller to place the shares, which will represent about 4.42% of the company's issued share capital after the placement, assuming no changes in the issued share capital until completion [1] - The company has conditionally agreed to issue 20.673 million new shares at the subscription price, which is the same as the placement price [1]

Core Viewpoint - The company, Ascentage Pharma-B (06855), has entered into a placement and subscription agreement to issue up to 22 million shares at a price of HKD 68.60 per share, which represents a discount to the market price, aiming to raise approximately HKD 15.09 billion for further commercialization and development of its core products [1][2][3] Group 1: Placement and Subscription Details - The placement price of HKD 68.60 per share is approximately 8.17% lower than the closing price of HKD 74.70 on the date of the agreement [2] - The maximum number of shares to be sold represents about 6.29% of the company's existing issued share capital as of the announcement date [1] - The expected net proceeds from the subscription are estimated to be around HKD 14.93 billion, with a net price per share of approximately HKD 67.84 [2] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated for commercialization efforts, including expanding coverage and improving patient access [3] - About 35% will be used for global clinical development to advance the company's core pipeline products [3] - The remaining 25% will be directed towards infrastructure and operational funding to strengthen global operations [3]